This story is from the CurrentWire archive. Coverage details reflect the last time it was updated.
Canada’s Drug Agency Issues Recommendation to Reimburse Yorvipath® (palopegteriparatide injection) With Conditions for Eligible Adults With Chronic Hypoparathyroidism
Recommendation is an important step toward potential public reimbursement for eligible adults whose chronic hypoparathyroidism is not adequately controlled with conventional therapy MONTREAL, Sept. 03, 2026 (GLOBE NEWSWIRE) — Pendopharm, a division of Pharmascience Inc., in collaboration with Ascendis Pharma A/S, today announced that Canada’s Drug Agency, or CDA-AMC, has recommended that Yorvipath® (palopegteriparatide injection) […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 19 minutes later, on .
Filed under Business · Canada · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Canada (18), Montreal (2), Drug Agency Issues Recommendation (none), Reimburse Yorvipath (none), Eligible Adults (none), Chronic Hypoparathyroidism (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.